News | News By Subject | News by Disease News By Date | Search News

Neutropenia News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Novartis AG (NVS)'s Sandoz Bags Approval for First Biosimilar to be Sold in the U.S.     3/9/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Amgen (AMGN) Release: Phase 3 Study Published In The Journal Of Clinical Oncology Shows First-Cycle Administration Of Neulasta Significantly Lowers Incidence Of Neutropenia With Related Fever And Hospitalization     2/28/2005
Amgen (AMGN) Release: Phase 3 Study Shows Majority Of Neutropenia With Related Fever And Hospitalization Occurs In First Treatment Cycle For Breast Cancer Patients Not Receiving Neulasta     12/13/2004
Maxygen, Inc. (MAXY) And Rentschler Biotechnologie GmbH & Co. Sign Agreement To Manufacture Novel G-CSF     9/9/2004

News from Around the Web
No News Posted on that date

Press Releases
Enzychem Lifesciences, Corp Announces Initiation Of Global Phase II Trial Of EC-18 In Patients With Chemotherapy Induced Neutropenia(CIN)     6/20/2017
U.S. FDA Accepts Biologics License Application (BLA) For Mylan (MYL) And BioCon (BIOCON.NS)'s Proposed Biosimilar Pegfilgrastim For Review     2/16/2017
BeyondSpring Pharmaceuticals Release: FDA Accepts Company IND Application For Plinabulin For The Prevention Of Chemotherapy-Induced Neutropenia     1/24/2017
BeyondSpring Pharmaceuticals Clinical Data On Neutropenia Mitigation With Plinabulin To Be Presented At 2016 American Society of Hematology Annual Meeting     11/4/2016
ASCO Selects BeyondSpring Abstract On Neutropenia Mitigation With Plinabulin Use For Publication     5/27/2016
New Patent Issued To Cantex Pharmaceuticals For Its Lead Product Candidate In The Treatment Of Thrombocytopenia And Neutropenia     3/2/2016
Nektar Therapeutics (NKTR) Announces Receipt Of $40 Million Milestone Payment Resulting From First Commercial Sale Of MOVENTIG (naloxegol) Tablets In Major European Market     9/1/2015
Allergan (AGN) Confirms Generic Noxafil Patent Challenge     8/12/2015
Spectrum Pharmaceuticals, Inc. (SPPI) Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for the Treatment of Chemotherapy-Induced Neutropenia     4/8/2013
Ligand Pharmaceuticals Inc. (LGND) Announces Positive Preclinical Data on Small-Molecule GCSF Receptor Agonist at the 53rd Annual Meeting of the American Society of Hematology     12/13/2011
BioGeneriX AG and Neose Technologies, Inc. (NTEC) Initiate Phase 2 Trial for GlycoPEG-GCSF     6/23/2008
Cleveland Biolabs Inc. (CBLI) Achieves Recovery From Neutropenia and Thrombocytopenia in Primates 48 Hours Post-Irradiation With Protectan CBLB502     12/4/2007
Merck & Co., Inc. (MRK) Study Presented on Use of CANCIDAS(R) (caspofungin acetate) as Empirical Therapy of Suspected Invasive Fungal Infections in Pediatric Patients with Persistent Fever and Neutropenia     9/17/2007
Neose Technologies, Inc. (NTEC) Announces BioGeneriX AG's Initiation Of Phase I Trial Of GlycoPEG-GCSF     11/9/2006
Amgen (AMGN) Release: Large Community-Based Clinical Trial In Older Cancer Patients Suggests Benefits Of Neulasta In First And Subsequent Cycles Of Chemotherapy     5/16/2005